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BACKGROUND: Preoperative peripheral blood neutrophil-to-lymphocyte ratio (NLR) has been proposed to predict
prognosis of hepatocellular carcinoma (HCC). However, the cutoff value of NLR in several studies is not consistent.
This study aims to investigate the correlation of preoperative NLR with clinicopathologic features and the
prognosis in patients who have undergone resection for HCC. METHODS: Clinical data of 256 patients with HCC
who underwent radical hepatectomy were retrospectively analyzed. The patients were divided into the low-NLR
group (NLR ≤ 2.31) and the high-NLR group (NLR N 2.31). A univariate analysis was performed to assess
clinicopathologic characteristics that influenced disease-free survival (DFS) and overall survival (OS) in patients.
The significant variables were further analyzed by a multivariate analysis using Cox regression. The Kaplan-Meier
method was used to assess the DFS and OS rate. RESULTS: The value of NLR was associated with tumor size,
clinical tumor-node-metastasis (TNM) stage, portal vein tumor thrombus (PVTT), distant metastasis, and aspartate
aminotransferase (AST) in HCC. NLR N 2.31, size of tumor N 5 cm, number of multiple tumors, III-IV of TNM stage,
PVTT, distant metastasis, and AST N 40 U/l were predictors of poorer DFS and OS. NLR N 2.31, size of tumor N5 cm,
III-IV of TNM stage, and AST N 40 U/l were independent predictors of DFS and OS. CONCLUSION: Preoperative NLR
N 2.31 was an adverse predictor of DFS and OS in HCC after hepatectomy. This study suggested that NLR might be a
novel prognostic biomarker in HCC after curative resection.
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Table 1. Patients with HCC (256 Cases) Categorized by NLR and Their Clinical Pathologic
Characteristics.
Clinical Character Variable No. of Patients NLR χ2 P Value
≤2.31 n (%) N2.31 n (%)
Age (yr) ≤ 55 176 81 (46.0) 95 (54.0) 0.349 .555
N 55 80 40 (50.0) 40 (50.0)
Gender Female 30 15 (50.0) 15 (50.0) 0.102 .750
Male 226 106 (46.9) 120 (53.1)
HBsAg Negative 41 18 (43.9) 23 (56.1) 0.222 .638
Positive 215 103 (47.9) 112 (52.1)
AFP (ng/ml) ≤ 20 62 31 (50.0) 31 (50.0) 0.245 .620
N 20 194 90 (46.4) 104 (53.6)
Tumor size (cm) ≤ 5 47 36 (76.6) 11 (23.4) 19.869 b .001
N 5 208 85 (40.7) 124 (59.3)
Cirrhosis No 27 14 (51.9) 13 (48.1) 0.255 .614
Yes 229 107 (46.7) 122 (53.3)
Tumor no. Single 163 79 (48.5) 84 (51.5) 0.259 .610
Multiple 93 42 (45.2) 53 (54.8)
TNM stage I-II 109 73 (67.0) 36 (33.0) 29.576 b .001
III-IV 147 48 (32.7) 99 (67.3)
PVTT No 184 98 (53.3) 86 (46.7) 9.434 .002
Yes 72 23 (31.9) 49 (68.1)
Distant metastasis No 218 111 (50.9) 107 (49.1) 7.858 .005
Yes 38 10 (26.3) 28 (73.7)
Recurrence No 164 71 (43.3) 93 (56.7) 2.890 .089
Yes 92 50 (54.3) 42 (45.7)
AST (U/l) ≤ 40 117 64 (54.7) 53 (45.3) 4.779 .029
N 40 139 57 (41.0) 82 (59.0)
NLR, neutrophil-to-lymphocyte ratio; HBsAg, hepatitis B surface antigen; AFP,α-fetoprotein; TNM,
tumor-node-metastasis; PVTT, portal vein tumor thrombus; AST, aspartate aminotransferase.
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An estimated 748,300 new liver cancer cases and 695,900 cancer
deaths occurred worldwide in 2008. Half of these cases and deaths
were estimated to occur in China [1]. There are significant
geographical differences in the morbidity and mortality of hepato-
cellular carcinoma (HCC) all over the world. HCC is one of the
common malignant tumors of digestive tract and is the major cancer
burden in China [2]. The prognosis of HCC remains poor mainly
because of high recurrence and metastasis rates even after surgical
resection. Tumor recurrence rates are more than 70% of cases at 5
years [3,4]. Although surgical resection is a potentially curative
treatment for HCC and despite improved diagnosis and advances in
surgical and nonsurgical therapy, the clinical outcome of HCC
remains poor [5]. Therefore, it is of great significance to carry out
deep research in diagnosis and prognosis of HCC. Such researches
might lead to a breakthrough in the field of HCC diagnosis,
treatment, and prevention and furthermore, adoption of effective
measures to improve surgical treatment for HCC.
Recently, there is increasing evidence that the presence of systemic
inflammation correlates with poor cancer-specific survival. The
prognostic value of various markers of systemic inflammatory,
including cytokines such as intercellular adhesion molecule 1 and
neutrophil-to-lymphocyte ratio (NLR) has been investigated in
certain cancer populations [6-14]. Previous studies have demonstrat-
ed that an elevated NLR may correlate with a poor prognosis in
patients who underwent curative resection of HCC. However, the
cutoff value of NLR is not consistent; for instance, it is determined
as 2.3 [15], 3.0 [16], and 5.0 [17,18] in different studies. So the
cutoff value of NLR in patients who underwent curative resection of
HCC should be optimized; otherwise, it is difficult to evaluate the
clinical value of NLR and to compare different studies. Our study
was designed to determine the optimal value of NLR and to evaluate
the correlation of preoperative NLR with clinicopathologic features
and prognosis in patients with HCC who underwent curative
resection.
Materials and Methods
The Source of Specimens and Clinical Data
Two hundred fifty-six cases of patients with HCC underwent
hepatic resection at the Affiliated Hospital of Guilin Medical
University (Guilin, People's Republic of China) from September
1999 to June 2007, and these patients were recruited for this study.
These subjects were confirmed by clinical, serological, ultrasonogra-
phy (US), computerized tomography, magnetic resonance imaging,
and pathologic examination, and HCC diagnoses in this study
followed the Primary Liver Cancer Clinical Diagnosis and Staging
Criteria (Ministry of Health, Beijing, China). Clinicopathologic
characteristics of these patients including NLR, age, gender, hepatitis
B surface antigen (HBsAg), α-fetoprotein (AFP), the size and the
number of tumors, combined liver cirrhosis, clinical tumor node
metastasis (TNM) stage, portal vein tumor thrombus (PVTT), distant
metastasis, and aspartate aminotransferase (AST) were collected and
detailed in Table 1. All subjects gave written informed consent, and
the local ethics committee approved this study. This study was
conducted as a retrospective analysis of a prospectively collected
computerized database in a single hospital. Among them, 256 patients
who met the inclusion criteria were enrolled in this study. Patients
were obviated if they 1) were patients with cholangiocarcinoma orwere not primary patients with HCC, 2) died in perioperative period,
3) could not provide detailed and needed clinical data, 4) had clinical
evidence of infection, immune-system disease, or hematology disease
or used hematology-influenced drugs within 1 month, 5) lost contact
during the follow-up time, or 6) were HIV positive.
Our research group investigated patients with HCC with long-
term follow-up after surgery including using serum AFP test and US
examination every 2 months and chest radiography every 6 months
during the first two postoperative years and at 3- to 6-month intervals
thereafter. Computerized tomography or magnetic resonance imaging
scans were performed if recurrence was suspected due to an abnormal
AFP test or US examination. The mean postoperative follow-up time
was 38.0 months (median, 21.0 months; range, 2.0-161.0 months).
Disease-free survival (DFS) was measured from the date of surgery to
the date of recurrence, metastasis, death, or last follow-up. Overall
survival (OS) was measured from the date of surgery to the date of
death or last follow-up.
Selection of Cutoff Score
To avoid predetermined cut point, receiver operating characteristic
(ROC) curve analysis was applied to define the cutoff score for
preoperative NLR. The score was selected as the cutoff value that was
closest to the point with both maximum sensitivity and specificity.
Other clinicopathologic parameters used were dichotomized: age
(≤55 vs N55 years), gender (female vs male), HBsAg (negative vs
positive), AFP level (≤20 vs N20 ng/ml), tumor size (≤5 vs N5 cm),
cirrhosis (yes vs no), tumor number (single vs multiple), TNM stage
(I-II vs III-IV), distant metastasis (yes vs no), PVTT (yes vs no),
recurrence (yes vs no), and AST (yes vs no). Subsequently, the
clinicopathologic and prognostic significance of the NLR level in
HCC was investigated.
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SPSS13.0 (SPSS Inc, Chicago, IL) and MedCalc statistical software
version 11.3.0.0 (MedCalc Software, Broekstraat 52 Mariakerke,
Belgium) were used in analyzing the data. The Pearson χ2 test was
used to compare qualitative variables. Univariate analysis was
performed to determine the significance of variables using the logistic
regression model for the response rate and the Cox regression model
for DFS and OS. Survival curve was estimated by Kaplan-Meier
analysis, and the log-rank test was used to examine the difference of
survival distributions between groups. Subsequently, the variables
with P b .05 were subjected to multivariate analysis. Cox
proportional hazards regression model was used to determine the
independent prognostic factors. A value of P b .05 was considered
significant.
Results
An Optimal Cutoff Value for Elevated NLR
According to the ROC curve, the optimal cutoff value of
preoperative NLR that had a relatively high specificity was 2.31.
The area under the ROC curves was 0.723 with a 95% confidence
interval (95% CI) for the area between 0.664 and 0.777. A cutoff
value of 2.31 presented a sensitivity of 59.1% and a specificity of
79.4% (Figure 1).
The Preoperative NLR in Patients with HCC and Its
Relationship with Clinical Pathologic Characteristics
As shown in Table 1, the relationship between preoperative
peripheral blood NLR and clinical pathologic characteristics was
investigated. One hundred thirty-five patients (52.73%) identified
as high-NLR group had an elevated NLR (N2.31), and 121
patients (47.27%) were identified as low-NLR (≤2.31) group.
Preoperative NLR level was closely correlated with the tumor size
(range, N5cm) (χ2 = 19.869; P b .001), clinical TNM stage (χ2 =
29.576; P b .001), PVTT (χ2 = 9.434; P = .002), distant
metastasis (χ2 = 7.858; P = .005), and AST (χ2 = 4.779, P = .029).
No obvious correlations with age, gender, HBsAg, AFP (N20 ng/ml),
and combination of liver cirrhosis and the number of tumors were
observed (P N .05).Figure 1. ROC curve to assess the predictive value of the NLR in
patients with HCC who underwent curative resection is shown.Association of NLR or Clinical Pathologic Index between
Postoperative DFS and OS
Kaplan-Meier survival analysis showed that NLR N 2.31 was
associated with a shorter DFS (Figure 2A) and OS (Figure 2B).
Univariate analysis revealed that obvious association existed between
clinical parameters and both DFS and OS (Table 2). Mean DFS in
patients with NLR ≤ 2.31 was 69.47 months (95% CI, 56.93-82.01)
compared with 30.23 months (95% CI, 21.99-38.48) in patients
with NLR N2.31 (P b .001). Mean OS in NLR ≤ 2.31 group and
NLR N 2.31 group was 76.15 months (63.35-88.96) and 37.96
months (28.52-47.40), respectively (P b .001). In addition to high-
NLR group (NLR N 2.31), size of tumor N5cm, multiple tumor
number, III-IV of TNM stage, and combination of PVTT, distant
metastasis, and AST N 40 U/l were also associated with a shorter DFS
and OS, and recurrence was associated with a shorter OS (Table 2).
As mentioned above, the cutoff value of NLR was selected as 3.0 [16]
or 5.0 [17,18] in previous reports, so we also evaluated the patients
with HCC in this study using these cutoff values. Kaplan-Meier
survival analysis showed that NLR N3.0 (Figure 2, C and D) and 5.0
(Figure 2, E and F) were associated with a shorter DFS and OS, but
there are 81 (31.64%) cases with NLR N3.0 in 256 patients with
HCC (Figure 2, C and D) and only 29 (11.33%) cases with NLR
N5.0 in 256 patients with HCC (Figure 2, E and F).
Independent Predictors of DFS and OS in the Stepwise
Multivariate Cox Proportional Hazards Model
The Cox proportional hazards model was used to examine the
association between clinicopathologic factors and DFS/OS after
surgical resection of HCC (Table 3). After adjusting other
confounding factors, except recurrence factor for OS, seven
associated factors (high NLR, size of tumor N5 cm, multiple
tumor number, III-IV of TNM stage, and combination of PVTT,
distant metastasis, and AST N 40 U/l) were analyzed for DFS and
OS using the stepwise multivariate Cox proportional hazards
model. Four factors were significant in the Cox proportional
hazards model. The hazard ratio (HR), 95% CI, and P values of
the four independent predictors are listed in Table 3. A stepwise
multivariate Cox proportional hazards model revealed that high
NLR (HR, 1.690; 95% CI, 1.247-2.291; P = .001), size of tumor
N 5 cm (HR, 1.974; 95% CI, 1.200-3.247; P = .007), III-IV of
TNM stage (HR, 1.727; 95% CI, 1.183-2.520; P = .005) and
AST N 40 U/l (HR, 1.888; 95% CI, 1.391-2.563; P b .001) were
independent predictors for DFS (Table 3). High NLR (HR, 1.639;
95% CI, 1.212-2.218; P = .001), size of tumor N5 cm (HR,
1.922; 95% CI, 1.168-3.162; P = .010), III-IV of TNM stage
(HR, 1.806; 95% CI, 1.236-2.638; P = .002), and AST N 40 U/l
(HR, 1.916; 95% CI, 1.415-2.595; P b .001) were independent
predictors for OS (Table 3).
Kaplan-Meier analysis of DFS and OS in 256 patients with
HCC Based on Statistically Significant Clinical Parameters
We established a preoperative prognostic score model by
calculating the number of independent predictors (NLR, size of
tumor, TNM stage, and AST) for each patient. Each factor was
allotted a score of 1, and then patients were divided into five
categories by their risk scores (RSs) (0, 1, 2, 3, and 4). For example,
“RS = 0” means patients without any of the above factors; this group
occupied 8.59% (22 of 256). “RS = 4” means patients with all four
factors; it occupied 26.56% (68 of 256) of patients carrying all four
Figure 2. (A and B) Kaplan-Meier survival analysis of patients with NLR N 2.31 having a shorter DFS and OS. The solid line represents the
NLR ≤ 2.31, whereas the dashed line represents the NLR N 2.31. (C and D) Kaplan-Meier survival analysis of patients with NLR N 3.0
having a shorter DFS and OS. The solid line represents the NLR≤ 3.0, whereas the dashed line represents the NLR N 3.0. (E and F) Kaplan-
Meier survival analysis of patients with NLR N 5.0 having a shorter DFS and OS. The solid line represents the NLR ≤ 5.0, whereas the
dashed line represents the NLR N 5.0.
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DFS and OS between patients whose RS equals 0 or 1 (Figure 3, A
and C; P = .132 and P = .145, respectively), these patients weremerged as score ≤ 1 group. By combining four independent
predictors, patients with different RSs showed distinguishable DFS
(RS ≤ 1 vs RS = 2, P b .001; RS = 2 vs RS = 3, P = .037; and RS = 3 vs
Table 2. Association between NLR, Clinical Parameters, and DFS/OS.
Clinical Character Category No. of
Patients
DFS (Mo) OS (Mo)
Mean 95% CI P Value Mean 95% CI P Value
NLR ≤ 2.31 121 69.47 56.93-82.01 b .001 76.15 63.35-88.96 b .001
N 2.31 135 30.23 21.99-38.48 37.96 28.52-47.40
Age (yr) ≤ 55 176 48.07 38.75-57.40 .526 56.48 45.99-66.98 .292
N 55 80 50.74 36.96-64.51 55.96 42.70-69.22
Gender Female 30 54.99 33.09-76.89 .167 63.04 42.58-83.51 .095
Male 226 47.49 39.35-55.63 55.50 46.42-64.58
HBsAg Negative 41 48.52 28.94-68.10 .834 53.32 34.40-72.24 .968
Positive 215 48.60 40.26-56.95 57.00 47.56-66.45
AFP (ng/ml) ≤ 20 62 45.72 30.28-61.17 .867 54.07 39.10-69.03 .764
N 20 194 49.74 40.80-58.69 57.48 47.52-67.43
Tumor size (cm) ≤ 5 47 98.96 79.86-118.07 b .001 111.32 89.55-133.08 b .001
N 5 208 37.63 30.00-45.26 42.50 34.96-50.04
Cirrhosis No 27 44.74 21.99-67.50 .334 48.33 26.29-70.38 .518
Yes 229 49.22 40.98-57.45 58.08 48.89-67.27
Tumor no. Single 163 58.20 47.84-69.56 .001 66.93 55.42-78.44 .003
Multiple 93 28.03 20.41-35.65 33.78 26.12-41.44
TNM stage I-II 109 79.01 65.64-92.37 b .001 92.80 78.33-107.27 b .001
III-IV 147 25.45 18.90-32.00 28.78 22.26-35.29
PVTT No 184 58.24 48.50-67.98 b .001 69.04 58.32-79.75 b .001
Yes 72 22.21 14.72-29.69 23.63 16.22-31.03
Distant metastasis No 218 54.26 45.51-63.02 b .001 63.65 53.91-73.38 b .001
Yes 38 15.97 10.03-21.92 19.61 13.06-26.15
Recurrence No 164 48.70 39.15-58.25 .002
Yes 92 66.52 52.39-80.64
AST (U/l) ≤ 40 117 71.03 58.08-83.98 b .001 82.74 68.40-97.08 b .001
N 40 139 30.93 22.84-39.03 34.67 26.70-42.64
NLR, neutrophil-to-lymphocyte ratio; HBsAg, hepatitis B surface antigen; AFP, α-fetoprotein; TNM, tumor-node-metastasis; PVTT, portal vein tumor thrombus; AST, aspartate aminotransferase.
Table 3.Cox Multivariate Proportional Hazards Model of Independent Predictors on DFS and OS.
Variable HR (95% CI) P Value
DFS
NLR (≤ 2.31 vs N 2.31) 1.690 (1.247-2.291) .001
Tumor size, cm (≤ 5 vs N 5) 1.974 (1.200-3.247) .007
Tumor no. (single vs multiple) 1.167 (0.864-1.576) .313
TNM stage (I-II vs III-IV) 1.727 (1.183-2.520) .005
PVTT (no vs yes) 1.192 (0.850-1.672) .309
Metastasis (no vs yes) 1.463 (0.996-2.147) .052
AST, U/l (≤ 40 vs N 40) 1.888 (1.391-2.563) b .001
OS
NLR (≤ 2.31 vs N 2.31) 1.639 (1.212-2.218) .001
Tumor size, cm (≤ 5 vs N 5) 1.922 (1.168-3.162) .010
Tumor no. (single vs multiple) 1.045 (0.771-1.416) .776
TNM stage (I-II vs III-IV) 1.806 (1.236-2.638) .002
PVTT (no vs yes) 1.400 (0.995-1.970) .054
Distant metastasis (no vs yes) 1.377 (0.934-2.030) .106
AST, U/l (≤ 40 vs N 40) 1.916 (1.415-2.595) b .001
CI, confidence interval; NLR, neutrophil-to-lymphocyte ratio; TNM, tumor-node-metastasis;
PVTT, portal vein tumor thrombus; AST, aspartate aminotransferase.
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RS = 2 vs RS =3, P = .015; and RS = 3 vs RS = 4, P b .001)
(Figure 3D). Surprisingly, the proportion of patients with HCC with
RS = 4 was very high, occupying 26.56% (68 of 256) of total patients
(Figure 3A). The DFS and OS in 68 patients with a score of 4
decreased sharply, and all these patients showed much shorter DFS
and OS.
Discussion
Experimental and clinical data indicate that chronic inflammation
significantly contributes to cancer development. The presence of
systemic inflammation is associated with poor survival in certain
tumors [15]. Inflammation can promote all stages of tumor
development through multiple mechanisms, which include predis-
posing tumor cell to proliferation and resistance to apoptosis,
induction of DNA mutations, and promotion of angiogenesis,
invasion, and metastasis [19]. The prognostic value of some systemic
inflammatory markers such as C-reactive protein [15] and NLR have
been investigated in tumor patients.
Inflammatory environments can accelerate the progression of
metastasis by neutrophi- mediated mechanisms [20]. NLR reflects an
inflammatory status; a preoperatively high ratio is most likely to reflect
more aggressive disease and hence represents poorer outcome. Patients
with tumor and elevated NLR have a relative lymphocytopenia and
neutrophilic leukocytosis, which denote that the balance is tipped in
favor of protumor inflammatory response leading to poor oncologic
outcome. The measurement of NLR would be of substantial value in
evaluating prognosis of some malignancies like colon cancer, gastric
cancer [6,7], lung cancer [8], renal cell carcinoma [9,10], breast cancer
[11], colorectal cancer [12], pancreatic cancer [13], and soft-tissue
sarcoma [14].
NLR as a prognostic marker in patients with HCC attracted more
and more researchers’ attention [15-18]. As we know, the NLR is amarker of systemic inflammation that is easily measured, easily
calculated from routinely available data, highly repeatable, and
inexpensive [21]. In this study, we authenticated that the optimal
cutoff value of NLR was 2.31 according to the ROC curve
(Figure 1). NLR appeared to be associated with tumor size, clinical
TNM stage, PVTT, distant metastasis, and AST in HCC (Table 1).
The NLR N 2.31 was identified as a factor for lower survival in
patients with HCC. Patients with elevated NLR (N2.31) had a
significantly shorter DFS and OS than those with low NLR (≤ 2.31)
(Figure 2, Table 2). Consistent with previous findings [16-18], NLR
N3.0 (Figure 2, C and D) and 5.0 (Figure 2, E and F) were also
associated with a shorter DFS and OS, but there were 81 (31.64%)
cases with NLR N3.0 in 256 patients with HCC (Figure 2, C and
D) and only 29 (11.33%) cases with NLR N5.0 in 256 patients with
Figure 3. Kaplan-Meier analysis of DFS and OS in 256 of patients with HCC who underwent curative resection by four independent
predictors. According to RS calculated from the four independent predictors (NLR N2.31, size of tumor N5 cm, III-IV of TNM stage,
and AST N40 U/l), all patients were divided into five groups (0, 1, 2, 3, and 4) (A and C) or four groups (≤1, 2, 3, and 4) (B and D); and
DFS (A and B) or OS (C and D) is compared.
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HCC are excluded using NLR N3.0 or 5.0; therefore, the cutoff
value 2.31 of preoperative NLR had a higher sensitivity in patients
with HCC than 3.0 or 5.0. It is noteworthy that 2.31 of
preoperative NLR as an optimal cutoff value in patients with
HCC is confirmed not only by this retrospective study but also by
some prospective clinical trials [15,22].
The association between elevated NLR and poor prognosis is
complex and remains to be elucidated. NLR is derived from the value
of neutrophils and lymphocytes, both of which are major parts of white
blood cells. Neutrophils mediate inflammatory response by release of
arachidonic acid metabolites and platelet-activating factors, whereas a
relative lymphopenia reflects the cortisol-induced stress response [23].
On the one hand, relatively increased number of circulating
neutrophils may increase the levels of circulating angiogenesis-
regulating chemokines, growth factors, and proteases (for instance,
CXCL8, also known as IL-8 [24], vascular endothelial growth factor,
matrix metallopeptidase 9 [25], and intercellular adhesion molecule 1
[26], all of which contribute to cancer development and progression by
regulating cell growth, angiogenesis, or inflammation [27] and could
serve as a predictor for poor survival in patients with HCC [28]).
However, the host’s immune response to tumor is lymphocytedependent. Patients with elevated NLR usually have relative
lymphocytopenia, and this may result in poorer lymphocyte-mediated
immune response to tumor, leading to a worse prognosis and a greater
chance of tumor recurrence and metastases. As we know, lymphocytes
play key roles in cytotoxic cell death and cytokine production that
inhibits tumor cells’ proliferation and metastatic competence [29];
therefore, patients with HCC with weaker lymphocytic infiltration in
tumor would have worse prognosis [30].
Up to now, there have been some different models that have
limited prognostic value in HCC [31,32]. On the basis of
multivariate analysis, we have established a simple preoperative
prognostic multiple-factor score model; we found that high NLR,
size of tumor N 5 cm, III-IV of TNM stage, and AST N 40 U/l were
identified as independent prognostic factors for DFS (Figure 3, A
and B, and Table 3) and OS (Figure 3, C and D, and Table 3). This
is consistent with several previous reports that tumor size N5 cm was
a significant risk factor of recurrence after liver resection [33-35]
and AST is an independent predictor for DFS in patients with HCC
[36-38]. Patients with HCC with small tumors (b5 cm) have a
better prognosis [39,40]; larger tumors (N5 cm) are reported to be
associated with greater likelihood of vascular invasion and higher
recurrence risk [33,34].
254 Neutrophil-To-Lymphocyte Ratio and Outcomes of HCC Liao et al. Translational Oncology Vol. 7, No. 2, 2014The follow-up data by univariate analysis revealed that tumor size
N 5 cm, multiple tumor number, III-IV of TNM stage, PVTT,
distant metastasis, and AST N 40 U/l were associated with a shorter
DFS and OS, and recurrence was associated with a shorter OS
(Table 2). Although univariate analysis in this study showed that
multiple tumor number, PVTT, and distant metastasis were
preoperative prognostic predictors of poor DFS and OS, none of
these factors were identified as independent predictors by multivariate
analysis (Table 3). However, this result did not mean that these
factors are not associated with recurrence and metastasis and are not
potential prognostic factors for HCC after resection. For example,
tumor number indicating a unifocal or multifocal tumor origin is an
important determinant of prognosis in patients with HCC
undergoing several kinds of treatments, and individuals with solitary
HCC have relatively better survival rate and prognosis than those
with multinodular tumors [41]. Previous study has also shown that
PVTT is an independent predictor of microvascular invasion [42].
The main cause of metastatic and recurrence in HCC is that tumor
cells tend to invade portal veins leading to PVTT, which is a unique
manner of HCC dissemination and is associated with poor prognosis
of HCC [43,44]. PVTT, arising from the invasion of HCC cells into
the portal vein, is well acknowledged as a special type of metastasis in
HCC [45] that is characterized by vascular invasion and a more
aggressive phenotype.
Taken together, our results showed that high NLR (N 2.31) was
an independent predictor for DFS and OS; elevated preoperative
NLR reflecting tumor burden, invasion, and metastasis indirectly
suggested that NLR might be a novel biomarker for HCC prognosis.
We established a multiple-factor scoring system in which NLR is a
major component to predict each patient’s prognosis. According to
the four independent predictors (high NLR, size of tumor N 5 cm,
III-IV of TNM stage, and AST N 40 U/l) of the score model, the
patients with postoperative HCC were separated into four distinct
RS groups with significantly different prognoses. Of note, limited by
the retrospective nature of this study and the small single-center
sample size, further multicenter, larger prospective studies are
required to validate this finding.
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